Treatment of COVID-19-Induced Systematic Inflammatory Response and Multiple Organ Failure Using Xuebijing

Author:

Chen Yao1,Guo Jianbo2,Peng Wei3,Xiang Xiangyin4,Wang Yifan2,Luo Yi2,Feng Yibin2,Wong Vivian Taam2,Chen Haiyong2ORCID

Affiliation:

1. Chengdu Second People's Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu, China

2. School of Chinese Medicine, The University of Hong Kong, Hong Kong, China

3. Chengdu University of Traditional Chinese Medicine, Sichuan Provincial Orthopedics Hospital, Chengdu, China

4. Ruian Hospital of Traditional Chinese Medicine, Ruian, China

Abstract

ABSTRACT According to clinical studies, patients with severe coronavirus disease 2019 (COVID-19) have a high incidence of cytokine storm and thrombosis. The National Health Commission of China approved Xuebijing (XBJ) as a first-line Chinese medicinal injection for COVID-19 patients with systemic inflammatory response syndrome (SIRS) and/or multiple organ failure (MOF). We hypothesized that the therapeutic effect of XBJ on SIRS and MOF in COVID-19 occurs via immunothrombosis and employed network pharmacology to evaluate this potential mechanism. The chemical compounds in XBJ were retrieved, and proteins related to thrombotic diseases were screened. Further, Gene Ontology enrichment analysis of the antithrombotic targets of XBJ was conducted. The results highlight the key inter-players (neutrophils, monocytes/macrophages, and platelets) of immunothrombosis in COVID-19 and the potential therapeutic mechanism of XBJ in suppressing oxidative stress, inflammation, apoptosis, and platelet aggregation. Severe COVID-19 patients with SIRS and MOF may benefit from XBJ as it exhibits anti-inflammatory effects, inhibits platelet activation, and induces lymphocyte apoptosis.

Publisher

Ovid Technologies (Wolters Kluwer Health)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3